Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Ringing of the bell.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(325)
•••
Comment by Actuarialon Feb 09, 2021 8:59am
109 Views
Post# 32510901

RE:RE:RE:Ringing of the bell.

RE:RE:RE:Ringing of the bell.Kazam1961, I have already told you "don't get back". The channel that you can flip ATE is closed, forever! LOL 

Kazam1961 wrote:
So Acturial, I haven't said boo on these boards and it is my Friuckin right to express my disgust for Dan's inept move. IF you are ok with the CEO with holding this type of news from you thats your perogative. Don't tell me how to invest...please. Next time I may not be so easy on you. If this is the type of crapp the CEO plays , then we really need to keep an eye on him. This is signicant news that should be shared with it it's stockholders. There is nothing about this that would constitute inside trading. In my opinion , shear ignorance on Dan's part. These boards are designed to share our trading ideas. IF you decide to continue beating on me, get ready for a shite storm that will bury yourself in HOURS of retort...GLTA


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities